Atrial Fibrillation in Young Patients: a Prospective Multicentre Registry

Atrial Fibrillation Clinical Trial

— YOUNG-AF  

Official title:

Atrial Fibrillation in Young Patients: a Prospective Multicentre Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04776759
• Other study ID #: Rythmo20200901
• Status: Recruiting
• Start date: January 1, 2021
• Est. completion date: January 1, 2031

Study information

• Verified date: August 2020
• Source: University Hospital, Caen
• Contact: Pierre Ollitrault, MD, MSc
• Phone: 0231063106
• Email: ollitrault-p[@]chu-caen.fr
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Atrial fibrillation is a rare cardiac arrhythmia in young (i.e. <= 35-year-old) patients. Etiological factors, current management and mid- to long-term outcomes remain unknown.

Description:

Atrial Fibrillation in YOUNG patients (YOUNG-AF) is a prospective, observational, multicentric registry, including every consecutive patients aged < 35-year-old with a diagnosis of atrial fibrillation. The registry will assess demographical, physical activity, toxicologic and genetic factors, as well as current management regarding anticoagulation, anti-arrhythmic drugs and catheter ablation. As an observational registry, patient will be managed with the guidelines-directed standard-of-care.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: January 1, 2031
• Est. primary completion date: January 1, 2031
• Gender: All
• Age group: N/A to 35 Years

Eligibility

Inclusion Criteria:

• First episode of atrial fibrillation

• Less than 35-year-old

• Diagnostic by 12-lead ECG or continuous monitoring (minimal duration 30 seconds)

• French Social Security number

Exclusion Criteria:

• Transvenous cardiac implantable electronic device (insertable cardiac monitors are not an exclusion criteria)

Related Conditions & MeSH terms

• Atrial Fibrillation
• Lone Atrial Fibrillation

Locations

Country	Name	City	State
France	Caen University Hospital	Caen	Normandy

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite of mortality, thromboembolic event and heart failure	Incidence of all-cause mortality, symptomatic thromboembolic event and congestive heart failure at 10-year after initial diagnosis of atrial fibrillation.	at 10-year
Primary	Recurrent symptomatic atrial fibrillation.	Incidence of symptomatic atrial fibrillation at 10-year after initial diagnosis of atrial fibrillation.	at 10-year